Captor Therapeutics ®
News
December 19, 2022
Captor Therapeutics senior management to hold investor and partnering meetings around J.P. Morgan 41st Annual Healthcare Conference
November 24, 2022
Captor Therapeutics reports Q3 2022 results and provides business update. Lead assets approaching the clinic and new significant drug discovery collaboration signed with Ono Pharmaceutical
November 14, 2022
Ono Pharmaceutical and Captor Therapeutics announce drug discovery collaboration to develop small molecule protein degraders for the treatment of neurodegenerative diseases
September 20, 2022
Captor Therapeutics announces participation in upcoming scientific, investor, and partnering conferences in October 2022
September 05, 2022
Captor Therapeutics' first half of 2022 marked by significant progress in R&D and preparations for the commencement of clinical trials
August 10, 2022
Captor Therapeutics nominates the molecular glue CPT-6281 as drug candidate to enter CTA/IND-enabling studies for the treatment of hepatocellular carcinoma
July 21, 2022
Captor Therapeutics to attend Wedbush PacGrow Healthcare Conference 2022
June 30, 2022
Zaproszenie na Walne Zgromadzenie